| Drug General Information |
| Drug ID |
D09NST
|
| Former ID |
DNCL002692
|
| Drug Name |
Afimoxifene
|
| Drug Type |
Small molecular drug
|
| Indication |
Breast cancer [ICD9: 174, 175; ICD10:C50]
|
Phase 2 |
[1]
|
|---|
| Company |
ASCEND Therapeutics
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C26H29NO2
|
| Canonical SMILES |
CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3
|
| InChI |
1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-
|
| InChIKey |
TXUZVZSFRXZGTL-QPLCGJKRSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
7494, 835333, 7889566, 10300358, 11532960, 14719814, 14719815, 14805025, 24895736, 24895814, 24899989, 26757818, 26759601, 36891034, 46393897, 47208207, 48243335, 49688682, 49846252, 50005439, 50065066, 53788270, 53789854, 56422185, 57404921, 57570889, 57654657, 77095723, 85788533, 87219226, 91613892, 93165645, 93167122, 103169566, 104640983, 124799764, 124893066, 126639485, 126671492, 126685161, 134341205, 135021191, 135065359, 135610264, 137156415, 142089319, 144208141, 162226886, 163414603, 163687254
|
| Target and Pathway |
| Target(s) |
Estrogen receptor |
Target Info |
Modulator |
[2]
|
|---|
|
KEGG Pathway
|
Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Endocrine and other factor-regulated calcium reabsorption
|
|
Proteoglycans in cancer
|
|
NetPath Pathway
|
FSH Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by HDAC Class II
|
|
Plasma membrane estrogen receptor signaling
|
|
LKB1 signaling events
|
|
Regulation of Telomerase
|
|
ATF-2 transcription factor network
|
|
AP-1 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Validated nuclear estrogen receptor alpha network
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
FOXA1 transcription factor network
|
|
Reactome
|
Nuclear signaling by ERBB4
|
|
Nuclear Receptor transcription pathway
|
|
WikiPathways
|
Estrogen signaling pathway
|
|
Nuclear Receptors Meta-Pathway
|
|
Estrogen Receptor Pathway
|
|
Signaling by ERBB4
|
|
JAK/STAT
|
|
Integrated Pancreatic Cancer Pathway
|
|
Leptin signaling pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
Integrated Breast Cancer Pathway
|
|
Nuclear Receptors
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00272714) Study of Afimoxifene Gel to Treat Cyclic Mastalgia in Premenopausal Women. U.S. National Institutes of Health. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). |
|---|
